Liraglutide is a synthetic GLP-1 receptor agonist used to improve blood sugar control in type 2 diabetes and to reduce cardiovascular risk in adults with established heart disease.
What it does
Liraglutide mimics GLP-1 (glucagon-like peptide-1), a hormone your gut releases after eating. It binds to GLP-1 receptors on pancreatic beta cells, triggering a rise in cAMP (cyclic adenosine monophosphate — an intracellular messenger) that prompts insulin release — but only when blood glucose is already elevated. This glucose-dependent mechanism is why liraglutide rarely causes hypoglycemia on its own PubMed 40014122. It simultaneously suppresses glucagon (the hormone that tells your liver to dump glucose into the bloodstream), and slows gastric emptying, which blunts post-meal glucose spikes PubMed 40330819.
Native GLP-1 breaks down in roughly 90 seconds, making it useless as a drug. Liraglutide solves this by attaching a fatty acid chain to the GLP-1 backbone, which causes it to bind to albumin in the blood and resist the enzymes (DPP-IV and neutral endopeptidases) that destroy natural GLP-1. The result is a plasma half-life of about 13 hours — long enough for once-daily dosing PubMed 40798976. Its amino acid sequence is 97% identical to human GLP-1, which minimizes immune reactions PubMed 41012437.
What the evidence shows
Type 2 diabetes — glycemic control Strong human trial evidence across multiple large RCTs
Liraglutide has been extensively studied in the LEAD (Liraglutide Effect and Action in Diabetes) trial program. Across these trials, liraglutide at 1.2–1.8 mg daily produced meaningful HbA1c reductions (a measure of average blood glucose over ~3 months) compared to placebo and active comparators including glimepiride and sitagliptin PubMed 40014122. It is approved for patients aged 10 and older with type 2 diabetes as an adjunct to diet and exercise PubMed 41300545. Evidence in pediatric populations is more limited but supports modest glycemic benefit in adolescents PubMed 41300545.
Cardiovascular risk reduction Strong human evidence — one large dedicated cardiovascular outcomes trial
The LEADER trial (over 9,000 adults with type 2 diabetes and high cardiovascular risk) found liraglutide reduced the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke compared to placebo — a roughly 13% relative risk reduction over a median follow-up of 3.8 years PubMed 40330819. This is one of the few diabetes drugs with a demonstrated mortality benefit in a dedicated outcomes trial, and it underlies liraglutide's formal cardiovascular indication NCT01744236.
Weight management Strong human evidence at higher doses (3 mg); moderate at diabetes doses (1.8 mg)
GLP-1 receptor agonism reduces appetite and food intake centrally, and liraglutide produces clinically meaningful weight loss in people with type 2 diabetes — typically 2–4 kg at therapeutic doses — alongside glycemic improvements PubMed 40014122. At the higher 3 mg dose (approved separately under the brand Saxenda for obesity), weight loss is more pronounced, averaging around 8% of body weight in trials. Self-reported use outside clinical settings mirrors these outcomes, though adherence and tolerability vary PubMed 41377305.
Circadian and metabolic effects Emerging — mostly mechanistic and early human data
GLP-1 receptors are expressed in brain regions involved in circadian rhythms (the body's internal 24-hour clock), and there is growing interest in whether GLP-1 agonists influence sleep quality and metabolic timing. Evidence here is early-stage, largely mechanistic, and not yet sufficient to support clinical claims PubMed 41898712.
Preconception and gestational contexts Limited human data; safety profile unclear
Some clinicians have explored liraglutide in women with obesity or prior gestational diabetes before conception NCT01234649. Current guidance recommends discontinuing liraglutide before pregnancy due to insufficient safety data in humans and fetal harm observed in animal studies PubMed 41377305.
How it's used
In clinical trials and approved prescribing, liraglutide is injected subcutaneously (under the skin) once daily, typically in the abdomen, thigh, or upper arm. Dosing starts at 0.6 mg daily for one week — this is a tolerability dose, not a therapeutic one — then steps up to 1.2 mg, and if needed to 1.8 mg for glycemic control PubMed 40014122. The dose escalation schedule exists to reduce GI side effects. Injection timing is flexible; liraglutide can be taken at any time of day, independent of meals PubMed 40330819. In studies and self-reported protocols, the range runs from 0.6 mg (initiation) to 1.8 mg (maximum approved diabetes dose). The 3 mg dose is a separate approved product for chronic weight management.
Side effects and safety
The most common side effects are gastrointestinal: nausea affects a substantial minority of users, particularly during dose escalation, and often improves after several weeks PubMed 40014122. Vomiting, constipation, and dyspepsia are also reported. Hypoglycemia is uncommon with liraglutide alone but becomes a real risk when combined with insulin or sulfonylureas PubMed 40330819.
Serious but rarer concerns include acute pancreatitis (inflammation of the pancreas); liraglutide carries a warning and should be stopped if pancreatitis is suspected. Animal studies showed a dose-dependent increase in thyroid C-cell tumors, raising concern for medullary thyroid carcinoma (MTC) — a rare cancer. Liraglutide is contraindicated in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN 2), a genetic syndrome linked to MTC risk PubMed 40014122. Whether this thyroid risk translates to humans remains uncertain; no causal signal has emerged in clinical trial populations to date, but surveillance is ongoing NCT01744236.
Long-term safety beyond 5 years, effects during pregnancy, and outcomes in pediatric populations with extended use are not yet well characterized PubMed 41300545.
Bottom line
Liraglutide has some of the strongest evidence of any diabetes drug for both glucose control and cardiovascular mortality reduction in high-risk patients. The gastrointestinal side effect burden is real but manageable for most people with a gradual dose titration. It is not appropriate for those with a personal or family history of medullary thyroid carcinoma, MEN 2, or active pancreatitis.